SCHEMBL6601388

SCHEMBL6601388

CCOc1cc(-c2ccccc2)nn1CCOc1ccc(-c2ccsc2)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.38
SLC6A9 P48067 1/20 0.38
HPGD P15428 1/20 0.37
ADORA2A P29274 2/20 0.36
TRPM4 Q8TD43 1/20 0.36
S1PR4 O95977 1/20 0.36
HTR1A P08908 1/20 0.35
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ATM Q13315 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6606052 0.94 HPGD (0.39) CREBBPSLC6A9HPGDADORA2ATRPM4
SCHEMBL6603543 0.93 ADORA2A (0.36) SLC6A9ADORA2ATRPM4HTR1AADORA2B
SCHEMBL6612367 0.90 TP53 (0.42) TRPM4MAPTKMT2ATP53MDM2
SCHEMBL6602658 0.90 HPGD (0.42) CREBBPHPGDS1PR4MAPTRAB9A
SCHEMBL6805998 0.88 HPGD (0.41) CREBBPHPGDS1PR4MAPTRAB9A
SCHEMBL6601689 0.86 SCN9A (0.38) SLC6A9
SCHEMBL6805880 0.86 CREBBP (0.40) CREBBPHPGDS1PR4MAPTRAB9A
SCHEMBL6604163 0.85 S1PR4 (0.40) CREBBPHPGDS1PR4MAPTRAB9A
SCHEMBL6607860 0.85 HPGD (0.40) CREBBPHPGDS1PR4MAPTRAB9A
SCHEMBL6604189 0.85 MAPT (0.43) CREBBPHPGDS1PR4MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 CREBBP 1352/4885SLC6A9 4650/4885HPGD 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.